About CLS
News and insights
©Copyright 2025 CLS AB. All rights reserved.
MM-2022-025/Rev2
Brain lesions such as tumors, epileptic foci and radiation necrosis means major challenges – for patients and for caregivers. In addition, they can be hard to access, making surgical resection difficult. Preserving critical tracts and cortex that control important functions of the body, so called eloquent structures, is crucial. In these cases, precision therapy with minimal-invasive laser ablation can be an appealing option.
When using laser ablation in neurosurgery, so-called laser interstitial thermal therapy (LITT), a region of interest is directly targeted and treated with high precision. This makes LITT an attractive alternative for various diseases and conditions affecting the brain, especially when the target area is hard-to-reach, or the patient is ineligible for open surgery.
LITT is minimally invasive using MRI-guidance (MRgLITT), and a stereotactic access system. The LITT procedure often requires shorter hospital stay and offers quicker patient recovery compared to open surgery.
Our system for LITT was cleared by the US Food and Drug Administration (FDA) in 2022 and is commercialized in the U.S. by our partner ClearPoint Neuro Inc. under the brand name ClearPoint Prism® Neuro Laser Therapy System.
The system is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy under magnetic resonance imaging (MRI) guidance in medicine and surgery in neurosurgery for a wavelength of 1064nm.
The use of Prism in combination with the neuro navigation access systems of ClearPoint Neuro ensures ease of use, high accuracy and workflow efficiency.
Clinical experience with the Prism system includes treatment of patients with tumors and other lesions in the brain, such as epileptogenic foci and radiation necrosis. Through continued investigation in emerging LITT applications, the method has the potential to expand to the treatment of a range of other pathologies.
Our goal is to continuously develop the therapy area – and to offer tailored tools for precise and cost-effective treatment.
“Across all uses, including treatment of brain tumors, radiation necrosis (RN), mesial temporal lobe epilepsy (MTLE), epilepsy secondary to hypothalamic hamartomas, and cavernous malformations, LITT is safe and efficacious, especially in patients who are ineligible for or not amenable to craniotomy”
LITT is particularly useful in treating recurrent brain metastases and glioblastomas (1). Clinical guidelines state that LITT should be considered as a potential option for inoperable patients with primary or recurrent brain tumors or metastases (2).
1 Seaton et al, World Neurosurgery 2025 2 AANS Position Statement 2021
Epilepsy affects 50 million people worldwide. One third of those are drug-resistant (two anti-seizure drugs failed) (1). Patients in this category may be evaluated for surgical intervention and are thus potential candidates for LITT (2).
LITT may be considered also for patients with radiation necrosis (1); a side effect occurring in up to 25% of radiation therapy cases. It can cause severe symptoms and even be life threatening (2).
1 NCCN Clinical Practice Guidelines 2024 (on file) 2 Radiation Necrosis – an overview
Webinar featuring Mark Richardson, MD, PhD. In this edition, neurosurgeon & professor, Dr. Mark Richardson discusses his first experiences and insights into the ClearPoint Prism System.
Thermoguide is part of the Prism therapy system and enables physicians to follow the progression of the ablation in near real-time and adjust treatment parameters as needed for optimal treatment outcome.
Wilson H et al. The ClearPoint Prism® Laser Ablation System: A New Platform for Laser Interstitial Thermal Therapy (LITT) in Neuro-Oncology Neurosurgery Practice 5(1):e00084, March 2024.
Last week we joined the 2024 Congress of Neurological Surgeons (CNS) meeting in Houston where our partner ClearPoint Neuro, Inc. exhibited the ClearPoint Prism® Neuro Laser Therapy System, powered by CLS. In addition to good booth traffic and customer discussions, we also took part in the scientific program providing the latest updates on the use of Laser Interstitial Thermal Therapy (LITT) in neurosurgery.
For the first time results from the CLS-sponsored study at Skåne University Hospital (SUS) will be presented and discussed during an international scientific congress. We are happy to share the abstract OP033 “Laser interstitial thermal therapy using an uncooled laser catheter in a diagnostic MR suite” by Dr Hjalmar Bjartmarz et al.
Since CLS´s laser ablation system for neurosurgery was cleared by the FDA in September last year development has progressed rapidly. But how does it actually work? We explain in this news post.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
©Copyright 2025 CLS AB. All rights reserved.
MM-2022-025/Rev2